NOD.Cg-Tg(Ins1-EGFP)1Hara/QtngJ

Stock number: 008173
Product name: NOD.B6-MIP-GFP
Strain synonyms: MIP-GFP (line 1)
Research areas: Diabetes and Obesity Research, Immunology, Inflammation and Autoimmunity Research, Research Tools

Description

Congenic NOD mice hemizygous for the MIP-GFP transgene have EGFP fluorescence in tissues where insulin I is normally detected, specifically in pancreatic beta-cells. Transgenic mice are reported to develop diabetes at a similar or higher rate and kinetics as wildtype controls. Transgenic mice may be useful in studies of diabetes and pancreatic beta islet cell biology.

Detailed description

Mice hemizygous for this "MIP-GFP" transgene are viable, fertile, normal in size and do not display any gross physical or behavioral abnormalities. These transgenic mice express Green Fluorescent Protein under the control of mouse insulin 1 promoter. Fluorescence is detected in tissues where insulin I is normally expressed; fluorescent protein expression in pancreatic beta-cells is evident from embryonic day (E)13.5 through adult. The human growth hormone sequence in the transgenic insert enhances expression of the EGFP but is not expressed.

The donating investigator reports NOD transgenic female mice develop insulitis and autoimmune diabetes at a similar rate and kinetics as female wildtype controls, 62% and 58% respectively, while surprisingly, transgenic males develop insulitis and diabetes at a higher rate than male wildtype controls, 65% and 10% respectively. This transgenic MIP-GFP mouse strain is useful in studies of diabetes and pancreatic beta islet cell biology.

In an attempt to offer alleles on well-characterized or multiple genetic backgrounds, alleles are frequently moved to a genetic background different from that on which an allele was first characterized. It should be noted that the phenotype could vary from that originally described. We will modify the strain description if necessary as published results become available.

Development

A transgenic construct containing the coding region of the Enhanced Green Fluorescent Protein (EGFP) gene and a 2.1kb sequence of the human growth hormone to confer high expression of the EGFP, under the control of the mouse insulin 1 gene promoter was injected into fertilized CD1 mouse eggs. Founder line 1 was established on a C57BL/6 background prior to mating to NOD. In 2008, the Type 1 Diabetes Resource received this transgenic NOD strain at generation N14 and mated to NOD/ShiLtJ (Stock No. 001976) for one generation prior to sibling mating.

Allele

Symbol: Tg(Ins1-EGFP)1Hara
Name: transgene insertion 1, Manami Hara
MGI accession ID: MGI:3704871
Generation method: Transgenic
Attributes: Reporter
Synonyms: MIP-GFP (line1); MIP:GFP; MIP-GFP; MIP-GFP (line 1); MIP-EGFP; Tg(Ins1-GFP)1Hara
Marker symbol: Tg(Ins1-EGFP)1Hara
Marker name: transgene insertion 1, Manami Hara
Chromosome: UN
Strain of origin: CD-1
Expressed genes: GFP,Green Fluorescent Protein,
Site of expression: EGFP expression is detected in tissues where insulin I is normally expressed; fluorescent protein expression in pancreatic beta-cells is evident from embryonic day (E)13.5 through adulthood.
Molecular note: A transgenic construct containing the coding region of the EGFP gene and a 2.1kb sequence of the human growth hormone to confer high expression of the EGFP, under the control of the mouse insulin 1 gene promoter (a 8.5 kb region including -8.5 to +12 bp relative to the transcriptional start site) was injected into fertilized CD1 mouse eggs. Founder line 1 was subsequently established. Fluorescence is detected in tissues where insulin I is normally expressed; fluorescent protein expression in pancreatic beta-cells is evident from embryonic day (E)13.5 through adult.